Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001926369 | SCV002199604 | uncertain significance | Jeune thoracic dystrophy; Nephronophthisis | 2022-03-10 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with TTC21B-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 710 of the TTC21B protein (p.Thr710Ala). |
Fulgent Genetics, |
RCV002484570 | SCV002785772 | uncertain significance | Asphyxiating thoracic dystrophy 4; Nephronophthisis 12 | 2022-01-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002558468 | SCV003662769 | uncertain significance | Inborn genetic diseases | 2022-11-03 | criteria provided, single submitter | clinical testing | The c.2128A>G (p.T710A) alteration is located in exon 15 (coding exon 15) of the TTC21B gene. This alteration results from a A to G substitution at nucleotide position 2128, causing the threonine (T) at amino acid position 710 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |